LONGEVERON INC-A (LGVN) Stock Fundamental Analysis
USA - NASDAQ:LGVN - US54303L2034 - Common Stock
0.8338 USD
0 (-0.42%)
0.85 USD
+0.02 (+1.94%)
Taking everything into account, LGVN scores 3 out of 10 in our fundamental rating. LGVN was compared to 534 industry peers in the Biotechnology industry. While LGVN seems to be doing ok healthwise, there are quite some concerns on its profitability. LGVN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
LGVN had negative earnings in the past year.
LGVN had a negative operating cash flow in the past year.
In the past 5 years LGVN always reported negative net income.
LGVN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LGVN has a Return On Assets of -111.58%. This is in the lower half of the industry: LGVN underperforms 77.90% of its industry peers.
LGVN has a worse Return On Equity (-147.66%) than 62.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -111.58% | ||
| ROE | -147.66% | ||
| ROIC | N/A |
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LGVN's Gross Margin of 78.77% is amongst the best of the industry. LGVN outperforms 84.27% of its industry peers.
LGVN's Gross Margin has improved in the last couple of years.
LGVN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
2. Health
2.1 Basic Checks
LGVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LGVN has been increased compared to 1 year ago.
LGVN has more shares outstanding than it did 5 years ago.
LGVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
LGVN has an Altman-Z score of -10.57. This is a bad value and indicates that LGVN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -10.57, LGVN is not doing good in the industry: 73.41% of the companies in the same industry are doing better.
There is no outstanding debt for LGVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.57 |
ROIC/WACCN/A
WACC8.75%
2.3 Liquidity
LGVN has a Current Ratio of 3.43. This indicates that LGVN is financially healthy and has no problem in meeting its short term obligations.
LGVN has a Current ratio of 3.43. This is in the lower half of the industry: LGVN underperforms 60.49% of its industry peers.
A Quick Ratio of 3.43 indicates that LGVN has no problem at all paying its short term obligations.
The Quick ratio of LGVN (3.43) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.43 | ||
| Quick Ratio | 3.43 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 83.52% over the past year.
LGVN shows a strong growth in Revenue. In the last year, the Revenue has grown by 68.67%.
The Revenue for LGVN have been decreasing by -15.76% on average. This is quite bad
EPS 1Y (TTM)83.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.97%
Revenue 1Y (TTM)68.67%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%-32.48%
3.2 Future
Based on estimates for the next years, LGVN will show a very strong growth in Earnings Per Share. The EPS will grow by 24.81% on average per year.
LGVN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 162.69% yearly.
EPS Next Y71.17%
EPS Next 2Y35.56%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue Next Year-41.66%
Revenue Next 2Y-32.85%
Revenue Next 3Y162.69%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LGVN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LGVN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LGVN's earnings are expected to grow with 24.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.56%
EPS Next 3Y24.81%
5. Dividend
5.1 Amount
No dividends for LGVN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.8338
0 (-0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.96%
Inst Owner Change3.25%
Ins Owners8.73%
Ins Owner Change7%
Market Cap17.56M
Revenue(TTM)2.07M
Net Income(TTM)-18688000
Analysts82.22
Price Target7 (739.53%)
Short Float %7.57%
Short Ratio2.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.22%
Min EPS beat(2)-1.78%
Max EPS beat(2)8.22%
EPS beat(4)2
Avg EPS beat(4)1.81%
Min EPS beat(4)-23.99%
Max EPS beat(4)24.81%
EPS beat(8)3
Avg EPS beat(8)-14.55%
EPS beat(12)3
Avg EPS beat(12)-13.25%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-32.05%
Min Revenue beat(2)-37.77%
Max Revenue beat(2)-26.32%
Revenue beat(4)1
Avg Revenue beat(4)4.88%
Min Revenue beat(4)-37.77%
Max Revenue beat(4)90.89%
Revenue beat(8)2
Avg Revenue beat(8)144.13%
Revenue beat(12)3
Avg Revenue beat(12)88.08%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.07%
EPS NY rev (1m)0%
EPS NY rev (3m)8.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-35.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-27.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.47 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.39 | ||
| P/tB | 1.7 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.44
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0.1
BVpS0.6
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -111.58% | ||
| ROE | -147.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.77% | ||
| FCFM | N/A |
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 87.51% | ||
| Cap/Sales | 49.01% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.43 | ||
| Quick Ratio | 3.43 | ||
| Altman-Z | -10.57 |
F-Score5
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)90.92%
Cap/Depr(5y)89.88%
Cap/Sales(3y)69.8%
Cap/Sales(5y)62.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.97%
EPS Next Y71.17%
EPS Next 2Y35.56%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue 1Y (TTM)68.67%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%-32.48%
Revenue Next Year-41.66%
Revenue Next 2Y-32.85%
Revenue Next 3Y162.69%
Revenue Next 5YN/A
EBIT growth 1Y-7.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.6%
OCF growth 3YN/A
OCF growth 5YN/A
LONGEVERON INC-A / LGVN FAQ
What is the ChartMill fundamental rating of LONGEVERON INC-A (LGVN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to LGVN.
What is the valuation status for LGVN stock?
ChartMill assigns a valuation rating of 1 / 10 to LONGEVERON INC-A (LGVN). This can be considered as Overvalued.
How profitable is LONGEVERON INC-A (LGVN) stock?
LONGEVERON INC-A (LGVN) has a profitability rating of 1 / 10.
Can you provide the financial health for LGVN stock?
The financial health rating of LONGEVERON INC-A (LGVN) is 6 / 10.